| Clinical use of sildenafil in pulmonary artery hypertension. | |
| | |
MedLine Citation:
|
PMID: 20387288 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Severe pulmonary hypertension is a debilitating disease with short life expectancy that often affects young people. It is usually idiopathic pulmonary artery hypertension and is characterized by progressive elevation of pulmonary artery pressure and vascular resistance, right ventricular failure and death with a limited median survival time. There is an imbalance in vasoconstrictive and vasodilatory substances. The phosphodiesterase-5 inhibitor sildenafil, a pulmonary and penile vasodilator initially approved for erectile dysfunction, is found to be efficacious in severe pulmonary artery hypertension. There are limited treatment options for the management of pulmonary artery hypertension in developing countries and sildenafil is a reasonable treatment option. This article reviews the relevant clinical data in pulmonary hypertension and the role of sildenafil in its management. |
| | |
Authors:
|
T P Singh |
Related Documents
:
|
19804228 - Sitaxsentan for the treatment of pulmonary arterial hypertension. 2148828 - Primary pulmonary hypertension and thromboembolic pulmonary hypertension--similarities ... 8985728 - Pulmonary hypertension of the newborn and urogenital anomalies in two male siblings: a ... 9719018 - Systemic hypertension and coronary artery disease. 22470808 - Multislice ct imaging of ruptured left sinus of valsalva aneurysm with fistulous track ... 18029278 - Hypertensive intracerebral hematoma after aneurysmal subarachnoid hemorrhage. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Expert review of respiratory medicine Volume: 4 ISSN: 1747-6348 ISO Abbreviation: Expert Rev Respir Med Publication Date: 2010 Feb |
Date Detail:
|
Created Date: 2010-04-13 Completed Date: 2010-06-10 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101278196 Medline TA: Expert Rev Respir Med Country: England |
Other Details:
|
Languages: eng Pagination: 13-9 Citation Subset: IM |
Affiliation:
|
Prime Heart and Vascular Institute, Shivalik Hospital, Sector-69, Mohali, Punjab, India. tpsinghtp@yahoo.co.in |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Oral Clinical Trials as Topic Drug Therapy, Combination Humans Hypertension, Pulmonary / drug therapy*, physiopathology Phosphodiesterase Inhibitors / administration & dosage, adverse effects, therapeutic use* Piperazines / administration & dosage, adverse effects, therapeutic use* Pulmonary Artery / physiopathology Purines / administration & dosage, adverse effects, therapeutic use Sulfones / administration & dosage, adverse effects, therapeutic use* Vasodilator Agents / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Phosphodiesterase Inhibitors; 0/Piperazines; 0/Purines; 0/Sulfones; 0/Vasodilator Agents; 139755-83-2/sildenafil |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: [Application of Monural to treat pregnant women with asymptomatic bacteriuria and acute cystitis].
Next Document: 14th congress of the APSR and 3rd Joint Congress of the APSR/ACCP.